Improvement in psoriasis after intradermal administration of heat-killed Mycobacterium vaccae

International Journal of Dermatology

Volumn 39, Issue 1, 2000, Pages 51-58

  Balagon, Maria V ^a,b,c   Walsh, Douglas S ^a,b,c   Tan, Paul L ^a,b,c   Cellona, Roland V ^a,b,c   Abalos, Rodolfo M ^a,b,c   Tan, Esterlina V ^a,b,c   Fajardo, Tranquilino T ^a,b,c   Watson, James D ^a,b,c   Walsh, Gerald P ^a,b,c  

^a Leonard Wood Memorial Center for Leprosy Research Philippines   (Philippines)

^b ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^c Genesis Research & Development Corporation Ltd   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPSORIASIS AGENT; CLOXACILLIN; CORTICOSTEROID; CYCLOSPORIN; ETRETINATE; METHOTREXATE; MYCOBACTERIUM VACCAE SUSPENSION; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG MECHANISM; EXFOLIATIVE DERMATITIS; FEMALE; HUMAN; MALE; MYCOBACTERIUM VACCAE; PSORIASIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BACTERIAL VACCINES; FEMALE; HUMANS; IMMUNOTHERAPY; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; MYCOBACTERIUM; PSORIASIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VACCINES, INACTIVATED;

EID: 0034053045     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-4362.2000.00862.x     Document Type: Article

References (40)

1. Guzzo C. Recent advances in the treatment of psoriasis. Dermatol Clin 1997; 15: 59-68.
2. z Griffiths TW, Griffiths CE, Voorhees JJ. Immunopathogenesis and immunotherapy of psoriasis. Dermatol Clin 1995; 13: 739-749.
3. de Rie MA, Bos JD. Cyclosporine immunotherapy. Clin Dermatol 1997; 15: 811-821.
4. Gottlieb S, Hayes E, Gilleaudeau P, et al. Cellular actions of etretinate in psoriasis: enhanced epidermal differentiation and reduced cell-mediated inflammation are unexpected outcomes. J Cutan Pathol 1996; 23: 404-418.
5. Fredriksson T, Pettersson U. Severe psoriasis: oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244.
6. Norris DA, Travers JB, Leung DYM. Lymphocyte activation in the pathogenesis of psoriasis. J Invest Dermatol 1997; 109: 1-4.
7. Bos JD, de Rie M. The pathogenesis of psoriasis: immunological facts and speculations. Immunol Today 1999; 20: 40-46.
8. Baker BS, Powles AV, Savage CR, et al. Intralesional cyclosporin in psoriasis: effects on T lymphocyte and dendritic cell subpopulations. Br J Dermatol 1989; 120: 207-213.
9. Baker BS, Griffiths CE, Lambert S, et al. The effects of cyclosporin A on T lymphocyte and dendritic cell subpopulations in psoriasis. Br J Dermatol 1987; 116: 503-510.
10. Gottlieb SL, Gilleaudeau P, Johnson R, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995; 1: 442-447.
11. 4antibody therapy of autoimmune and inflammatory disease. Clin Exp Immunol 1997; 110: 158-166.
12. Stanford JL, Stanford CA. Immunotherapy with Mycobacterium vaccae and the treatment of tuberculosis. Soc Appl Bacteriol Symp Ser 1996; 25: 81S-86S.
13. Stanford JL, Rook GA, Bahr GM, et al. Mycobacterium vaccae in immunoprophylaxis and immunotherapy of leprosy and tuberculosis. Vaccine 1990; 8: 525-530.
14. Stanford JL, Bahr GM, Rook GA, et al. Immunotherapy with Mycobacterium vaccae as an adjunct to chemotherapy in the treatment of pulmonary tuberculosis. Tubercle 1990; 71: 87-93.
15. Prior JG, Khan AA, Cartwright KA, et al. Immunotherapy with Mycobacterium vaccae combined with second line chemotherapy in drug-resistant abdominal tuberculosis. J Infect 1995; 31: 59-61.
16. Onyebujoh PC, Abdulmumini T, Robinson S, et al. Immunotherapy with Mycobacterium vaccae as an addition to chemotherapy for the treatment of pulmonary tuberculosis under difficult conditions in Africa. Respir Med 1995; 89: 199-207.
17. Corlan E, Marica C, Macavei C, et al. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis in Romania. 2. Chronic or relapsed disease. Respir Med 1997; 91: 21-29.
18. Corlan E, Marica C, Macavei C, et al. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis in Romania. 1. Newly-diagnosed pulmonary disease. Respir Med 1997; 91: 13-19.
19. Bahr GM, Stanford JL, Chugh TD, et al. An investigation of patients with pulmonary tuberculosis in Kuwait in preparation for studies of immunotherapy with Mycobacterium vaccae. Tubercle 1990; 71: 77-86.
20. Stanford JL, Stanford CA. Immunotherapy of tuberculosis with Mycobacterium vaccae NCTC 11659. Immunobiol 1994; 191: 555-563.
21. Lehrer A, Bressanelli A, Wachsmann V, et al. Immunotherapy with Mycobacterium vaccae in the treatment of psoriasis. FEMS Immunol Med Microbiol 1998; 21: 71-77.
22. Ramu G, Prema GD, Balakrishnan S, et al. A preliminary report on the immunotherapy of psoriasis. Indian Med Gazette 1990; 124: 381-382.
23. Horsburgh CR Jr. Epidemiology of disease caused by nontuberculous mycobacteria. Semin Respir Infect 1996; 11: 244-251.
24. Hachem R, Raad I, Rolston KV, et al. Cutaneous and pulmonary infections caused by Mycobacterium vaccae. Clin Infect Dis 1996; 23: 173-175.
25. Bahr GM, Shaaban MA, Gabriel M, et al. Improved immunotherapy for pulmonary tuberculosis with Mycobacterium vaccae. Tubercle 1990; 71: 259-266.
26. Pozniak A, Stanford JL, Grange JM. Mycobacterium vaccae immunotherapy [letter]. Lancet 1991; 338: 1533-1534.
27. Swinburne S, Brown IN, Brown CA. Mycobacterium vaccae and immune responses: implications for leprosy control. Lepr Rev 1985; 56: 209-220.
28. Brown CA, Brown IN, Swinburne S. The effect of oral Mycobacterium vaccae on subsequent responses of mice to BCG sensitization. Tubercle 1985; 66: 251-260.
29. Stanford JL, Grange JM. New concepts for the control of tuberculosis in the twenty first century. J R Coll Physicians Lond 1993; 27: 218-223.
30. Kon OM, Goyal M, Filley E, et al. Mycobacterium vaccae: a study of safety and outcome measures. Respir Med 1998; 92: 597-598.
31. von Reyn CF, Arbeit RD, Yeaman G, et al. Immunization of healthy adult subjects in the United States with inactivated Mycobacterium vaccae administered in a three-dose series. Clin Infect Dis 1997; 24: 843-848.
32. Marsh BJ, von Fordham Reyn C, Arbeit RD, Morin P. Immunization of HIV-infected adults with a three-dose series of inactivated Mycobacterium vaccae. Am J Med Sci 1997; 313: 377-383.
33. Wang CC, Rook GA. Inhibition of an established allergic response to ovalbumin in BALB/c mice by killed Mycobacterium vaccae. Immunol 1998; 93: 307-313.
34. Skinner MA, Yuan S, Prestidge R, et al. Immunization with heat-killed Mycobacterium vaccae stimulates CD8+ cytotoxic T cells specific for macrophages infected with Mycobacterium tuberculosis. Infect Immun 1997; 65: 4525-4530.
35. Michel G, Mirmohammadsadegh A, Olasz E, et al. Demonstration and functional analysis of IL-10 receptors in human epidermal cells: decreased expression in psoriatic skin, down-modulation by IL-8, and up-regulation by an antipsoriatic glucocorticosteroid in normal cultured keratinocytes. J Immunol 1997; 159: 6291-6297.
36. 3and calcipotriol induce IL-10 receptor gene expression in human epidermal cells. Inflamm Res 1997; 46: 32-34.
37. Kang S, Yi S, Griffiths CE, et al. Calcipotriene-induced improvement in psoriasis is associated with reduced interleukin-8 and increased interleukin-10 levels within lesions. Br J Dermatol 1998; 138: 77-83.
38. Leivo T, Leivo I, Kariniemi AL, et al. Down-regulation of transforming growth factor-beta receptors I and II is seen in lesional but not non-lesional psoriatic epidermis. Br J Dermatol 1998; 138: 57-62.
39. Hatta N, Takata M, Kawara S, et al. Tape stripping induces marked epidermal proliferation and altered TGF-alpha expression in non-lesional psoriatic skin. J Dermatol Sci 1997; 14: 154-161.
40. Asadullah K, Sterry W, Stephanek K, et al. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest 1998; 101: 783-794.